GSK and Neopharma launch first batch of UAE-made medicines

The launch was attended by representatives of GSK, Neopharma, the British embassy and the Abu Dhabi Department of Health, among others. (Image: Facebook/Department of Health, Abu Dhabi)

Dental Tribune International

Mon. 3. February 2020

save

GlaxoSmithKline (GSK), a global healthcare company, and Neopharma, a leading global pharmaceutical company based in the UAE, have launched the first locally produced batch of medicines. The aim of the partnership is to create manufacturing opportunities in the UAE.

The partnership, announced in April 2019, established Neopharma as GSK’s third-party manufacturer for handling the secondary packaging process (the final manufacturing stage) for six of GSK’s most prescribed medicines in the UAE. This first batch includes 35,000 packages of medicine manufactured at Neopharma’s plant in Abu Dhabi, and these are to be readily available to UAE patients within the next few weeks.

Sameh el-Fangary, GSK vice president and general manager for the Gulf cluster, said: “We are delighted to see the outcomes of our partnership with Neopharma already yielding results. As a result of this collaboration, the batch will reach UAE shelves two months earlier than planned. This is the most recent example of GSK’s commitment to ensuring a continuous supply of our high-quality, safe, and reliable medicines for patients in the UAE to access.”

Dr B.R. Shetty, founder and chairman of Neopharma, added: “It is wonderful to witness another landmark moment in our collaboration with GSK. We are delighted to partner with GSK to be able to provide local patients better access to medicines. By manufacturing the medicine locally, Neopharma has reinforced its commitment to maintaining global quality and manufacturing standards that are complying with stringent regulatory requirements.”